ECM
DNA icon

Evergreen Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Evergreen Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-693
Closed -$46.8K – 888
2023
Q4 		$46.8K Buy
+693
New +$42.4K ﹤0.01% 833
2022
Q2 		– Sell
-1,073
Closed -$173K – 602
2022
Q1 		$173K Buy
+1,073
New +$209K 0.01% 629

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Evergreen Capital Management's DNA Position: Q1 2024 in Review

Evergreen Capital Management sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 693 shares — an estimated $46.8K sold.

Evergreen Capital Management first reported a position in DNA in Q1 2022 and held it in 2 quarters. The position peaked at $173K in Q1 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • Evergreen Capital Management reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • Evergreen Capital Management sold 693 Ginkgo Bioworks shares in Q1 2024, an estimated $46.8K.
  • Evergreen Capital Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 2 quarters.
  • Evergreen Capital Management's Ginkgo Bioworks position peaked at $173K in Q1 2022.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Evergreen Capital Management's 13F filing for Q1 2024, filed 15 May 2024.